Meeting
2019 ASCO Annual Meeting
Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).
Authors
Hoyoung M. Maeng
National Cancer Institute, Bethesda, MD
Hoyoung M. Maeng , Lauren Virginia Wood , Brittni Moore , Mohammadhadi H. Bagheri , Santhana Webb , Lee England , Giselle Martinez , Seth M. Steinberg , Svetlana Pack , David Stroncek , John Charles Morris , Masaki Terabe , Jay A. Berzofsky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Vaccines
Clinical Trial Registration Number
NCT01730118
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2639)
DOI
10.1200/JCO.2019.37.15_suppl.2639
Abstract #
2639
Poster Bd #
283
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Final report and long-term outcomes: Phase I trial of a HER2 intracellular plasmid-based vaccine in HER2+ advanced stage breast cancer.
First Author: Mary L. Disis
Poster
2019 ASCO Annual Meeting
A phase Ib study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.
First Author: Yee Chao
Poster
2014 ASCO Annual Meeting
A phase I trial of the safety and immunogenicity of a DNA-based vaccine encoding the HER2/neu (HER2) intracellular domain in subjects with HER2+ breast cancer.
First Author: Mary L. Disis
Poster
2011 ASCO Annual Meeting
Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer.
First Author: D. Gajria